Market Cap 553.89M
Revenue (ttm) 43.47M
Net Income (ttm) -17.93M
EPS (ttm) N/A
PE Ratio 5.17
Forward PE 5.46
Profit Margin -41.25%
Debt to Equity Ratio 0.00
Volume 1,169,894
Avg Vol 3,101,286
Day's Range N/A - N/A
Shares Out 78.79M
Stochastic %K 9%
Beta 1.39
Analysts Strong Sell
Price Target $14.86

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 517 9500
Fax: 908 375 8272
Address:
300 Connell Drive, Suite 4200, Berkeley Heights, United States
stevemail
stevemail Feb. 23 at 8:32 PM
$CRMD this is dead
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Feb. 23 at 8:22 PM
$CRMD Very low volume today. I expect a 7 break near close.
1 · Reply
Sahil1991
Sahil1991 Feb. 23 at 7:38 PM
$CRMD While I'm wish fulfillment vibe. NVR, Inc. used buybacks to become one of the best-performing stocks of the last 30 years. (1) Phenomenal Returns: Since the 1990s, NVR has seen a total shareholder return (TSR) exceeding 40,000%, driven largely by their relentless share cannibalisation. (2) Consistent Buyback Levels: NVR consistently dedicated nearly all free cash flow to repurchases, often reducing their share count by 3% to 5% annually for decades. (3) Asset-Light/High Margin: By using land options rather than buying land (Asset-Light), they maintained Operating Margins consistently in the 15-20% range with industry-leading ROE. The CRMD Parallel: By prioritising a licensing-heavy model over traditional, capital-intensive R&D pipelines, CRMD can mirror NVR’s "land-option" strategy. This keeps the balance sheet lean while the superior margins (potential for 30%+) fund a consistent buyback program that compounds EPS regardless of broader market volatility.
1 · Reply
Sahil1991
Sahil1991 Feb. 23 at 7:16 PM
$CRMD Just speculation/wish fulfillment. Why Merck might buy CRMD: - Cheap - Already own the royalties and milestones for REZZAYO - Positive P3 REZZAYO - Turnkey salesforce (Melinta) - "Specialty, Pharma & Infectious Diseases" = CRMD "US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug. The firm is to split its healthcare business into two units: one housing its cancer portfolio and the other for non-cancer assets across the specialty, pharma and infectious-diseases categories. "As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma & Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating longterm value for our stakeholders," said chair and chief executive Robert Davis in a statement."
1 · Reply
Derfzilla
Derfzilla Feb. 23 at 7:12 PM
$CRMD c'mon, let's go
0 · Reply
Derfzilla
Derfzilla Feb. 23 at 7:06 PM
$CRMD good time to pick up some cheap shares
0 · Reply
firedupinvestors
firedupinvestors Feb. 23 at 6:41 PM
0 · Reply
BioLove
BioLove Feb. 23 at 6:32 PM
$CRMD haven't checked in a while. Just, wow.
0 · Reply
firedupinvestors
firedupinvestors Feb. 23 at 6:03 PM
$CRMD BOOM...BOOM ...BOOM how low do we go.
0 · Reply
Derfzilla
Derfzilla Feb. 23 at 6:02 PM
$CRMD more cowbell please
0 · Reply
Latest News on CRMD
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

Feb 14, 2026, 2:37 AM EST - 9 days ago

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript


CorMedix to Participate in Upcoming Investor Conferences

Feb 12, 2026, 8:30 AM EST - 11 days ago

CorMedix to Participate in Upcoming Investor Conferences


CorMedix Therapeutics Announces Share Repurchase Program

Feb 2, 2026, 8:30 AM EST - 21 days ago

CorMedix Therapeutics Announces Share Repurchase Program


CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:05 AM EST - 6 weeks ago

CorMedix Therapeutics Announces Leadership and Board Updates


CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 11:11 AM EST - 3 months ago

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript


CorMedix: Strong Adoption Curve And Policy Environment

Sep 22, 2025, 4:46 AM EDT - 5 months ago

CorMedix: Strong Adoption Curve And Policy Environment


CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 6 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH


CorMedix: The Undervalued Breakthrough

Aug 26, 2025, 2:41 AM EDT - 6 months ago

CorMedix: The Undervalued Breakthrough


CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:16 PM EDT - 7 months ago

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript


CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 10:49 AM EDT - 7 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million


CorMedix Analyst Says Investors Could Be Further Rewarded

Jun 30, 2025, 2:24 PM EDT - 8 months ago

CorMedix Analyst Says Investors Could Be Further Rewarded


CorMedix Seems Significantly Undervalued

Jun 30, 2025, 2:14 PM EDT - 8 months ago

CorMedix Seems Significantly Undervalued


CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 8 months ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock


CorMedix inc. Announces Customer Implementation

Jun 23, 2025, 7:30 AM EDT - 8 months ago

CorMedix inc. Announces Customer Implementation


CorMedix: Exceeding Expectations

Jun 4, 2025, 12:41 PM EDT - 9 months ago

CorMedix: Exceeding Expectations


CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:59 AM EDT - 10 months ago

CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript


stevemail
stevemail Feb. 23 at 8:32 PM
$CRMD this is dead
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Feb. 23 at 8:22 PM
$CRMD Very low volume today. I expect a 7 break near close.
1 · Reply
Sahil1991
Sahil1991 Feb. 23 at 7:38 PM
$CRMD While I'm wish fulfillment vibe. NVR, Inc. used buybacks to become one of the best-performing stocks of the last 30 years. (1) Phenomenal Returns: Since the 1990s, NVR has seen a total shareholder return (TSR) exceeding 40,000%, driven largely by their relentless share cannibalisation. (2) Consistent Buyback Levels: NVR consistently dedicated nearly all free cash flow to repurchases, often reducing their share count by 3% to 5% annually for decades. (3) Asset-Light/High Margin: By using land options rather than buying land (Asset-Light), they maintained Operating Margins consistently in the 15-20% range with industry-leading ROE. The CRMD Parallel: By prioritising a licensing-heavy model over traditional, capital-intensive R&D pipelines, CRMD can mirror NVR’s "land-option" strategy. This keeps the balance sheet lean while the superior margins (potential for 30%+) fund a consistent buyback program that compounds EPS regardless of broader market volatility.
1 · Reply
Sahil1991
Sahil1991 Feb. 23 at 7:16 PM
$CRMD Just speculation/wish fulfillment. Why Merck might buy CRMD: - Cheap - Already own the royalties and milestones for REZZAYO - Positive P3 REZZAYO - Turnkey salesforce (Melinta) - "Specialty, Pharma & Infectious Diseases" = CRMD "US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug. The firm is to split its healthcare business into two units: one housing its cancer portfolio and the other for non-cancer assets across the specialty, pharma and infectious-diseases categories. "As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma & Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating longterm value for our stakeholders," said chair and chief executive Robert Davis in a statement."
1 · Reply
Derfzilla
Derfzilla Feb. 23 at 7:12 PM
$CRMD c'mon, let's go
0 · Reply
Derfzilla
Derfzilla Feb. 23 at 7:06 PM
$CRMD good time to pick up some cheap shares
0 · Reply
firedupinvestors
firedupinvestors Feb. 23 at 6:41 PM
0 · Reply
BioLove
BioLove Feb. 23 at 6:32 PM
$CRMD haven't checked in a while. Just, wow.
0 · Reply
firedupinvestors
firedupinvestors Feb. 23 at 6:03 PM
$CRMD BOOM...BOOM ...BOOM how low do we go.
0 · Reply
Derfzilla
Derfzilla Feb. 23 at 6:02 PM
$CRMD more cowbell please
0 · Reply
Derfzilla
Derfzilla Feb. 23 at 5:59 PM
0 · Reply
barlaw
barlaw Feb. 23 at 5:41 PM
$CRMD Daily chart here is the poster child for Bill Murray’s Ground Hog Day: Green—> Red—>Green—>Red Traffic Light Ticker; Gridlock.
0 · Reply
Noname2022
Noname2022 Feb. 23 at 5:31 PM
$CRMD lower the better for share repurchases so long as before MA & Prophy catalysts…
2 · Reply
golfguy42360
golfguy42360 Feb. 23 at 5:31 PM
$CRMD 6 month low 6.78 getting close to it.
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 5:05 PM
$CRMD into Q4 earnings — buy the setup or brace for disappointment? 👀 DefenCath sales and Melinta product contributions are front and center this quarter, but muted 2026 guidance is hanging over the story. That mix could make this report a real sentiment mover. Positioning ahead of the print? Full breakdown here 👉 https://www.zacks.com/stock/news/2873652/should-investors-buy-sell-or-hold-crmd-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2873652-teaser-34677&ADID=SYND_STOCKTWITS_TWEET_2_2873652_TEASER_34677
1 · Reply
Czar100
Czar100 Feb. 23 at 4:56 PM
$CRMD My buy went through. 👇
0 · Reply
nanoled2020
nanoled2020 Feb. 23 at 4:35 PM
$CRMD Always feels like something keeps the price down for either a sale of the company, merger or raise.
0 · Reply
IntelligunInvestings
IntelligunInvestings Feb. 23 at 4:19 PM
$CRMD what is the "strong competition" I'm hearing about What's the point in making something new if someone can switch the finished product around to make a copy?
1 · Reply
wolverine
wolverine Feb. 23 at 4:13 PM
$CRMD so $350 million in revenue predicted this year but $550 million in market cap? Also that revenue include no new customers or indications. Pretty ridiculously undervalued!!
1 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 4:05 PM
$CRMD's uncertainty looms despite a strong DefenCath launch 🚨 🔍 Earnings estimates for 2026 have been cut 📉 Shares down nearly 49% in six months ⚠️ Strong competition could hinder long-term growth Is it time to reassess your position? Full analysis here 👉 https://www.zacks.com/stock/news/2873652/should-investors-buy-sell-or-hold-crmd-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2873652-body-34673&ADID=SYND_STOCKTWITS_TWEET_2_2873652_BODY_34673
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Feb. 23 at 4:03 PM
$CRMD While the one-month chart looks ugly, it's only a 5% decline during that time.
0 · Reply
m1gls
m1gls Feb. 23 at 3:54 PM
$CRMD "Many ESRD patients begin dialysis with a central venous catheter, which while necessary, poses a high infection risk. Although our long-term goal is to transition patients to permanent access bloodstream infection prevention remains even more critical during this period. Antimicrobial interventions reduce infection rates by 70% compared to conventional care. In August, we launched a program to further increase antimicrobial catheter treatments to eligible patients. Adoption to date has been strong, with 84% of eligible capita patients now receiving bloodstream infection protection, and we are on track to achieve even greater utilization". The last earning call (q3) transcription; page 3 $FMS
0 · Reply